Reuters logo
BRIEF-Tracon Pharmaceuticals receives special protocol assessment agreement from FDA
January 3, 2017 / 1:21 PM / 9 months ago

BRIEF-Tracon Pharmaceuticals receives special protocol assessment agreement from FDA

Jan 3 (Reuters) - Tracon Pharmaceuticals Inc

* Receives special protocol assessment (SPA) agreement from FDA for phase 3 clinical trial of TRC105 in angiosarcoma

* “Look forward to dosing first patients in trial during early 2017” Source text for Eikon: Further company coverage:

Our Standards:The Thomson Reuters Trust Principles.
0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below